CHIPS validated 21-day chilled platelets in cardiac surgery
The CHIPS adaptive randomized trial asked whether platelets refrigerated for up to 21 days could control bleeding in cardiac surgery patients as well as room-temperature units kept under 7 days. Between December 2021 and March 2025 the study enrolled 1,000 participants at 27 sites in the United States and Australia, roughly a third of them children undergoing operations that expected to need platelets. Patients received either standard room-temperature platelets or chilled units; after every 200 completed cases independent analysts reviewed hemostasis and safety, and if chilled storage remained non-inferior the protocol allowed adding up to 5 more storage days, to a ceiling of 21 days. Results published in JAMA show that 21-day refrigerated platelets matched room-temperature products for stopping surgical bleeding. Platelets today last only 5 to 7 days at room temperature, and Philip Spinella, who led CHIPS, argues rural hospitals and blood banks could keep stock far longer if regulators accept the finding. The decision sits with the Food and Drug Administration, which is weighing whether to widen use of cold-stored platelets beyond the current 14-day allowance.[1]
